Clinical Trial

Retrospective Study Evaluating the Effectiveness and Safety of Immunotherapy With Clustoid Max Forte

Completed
View on ClinicalTrials.gov →
Summary
House dust mites are the main source of allergies in indoor environments. They are predominant in coastal areas, with the Canary Islands being the autonomous community with the highest percentage of patients with rhinoconjunctivitis due to sensitisation to these mites (94.7%). Immunotherapy is indicated for the treatment of allergic rhinoconjunctivitis and is capable of altering the natural course of allergic diseases. The aim of the study was to evaluate the efficacy and safety of Clustoid® Max Forte in the treatment of patients with respiratory allergy to Dermatophagoides/Blomia tropicalis.
Trial Details
NCT Number NCT07427576
Lead Sponsor Inmunotek S.L.
Conditions Mite Allergy, Dermatophagoides Farinae Allergy, Dermatophagoides Pteronyssinus Allergy, Rhinitis, Allergic, Asthma, Rhinoconjunctivitis
Enrollment 140 participants
Start Date 2025-03-31
Primary Completion 2025-08-31 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-02-23